I think you're right about the chances of approval once there is efficacy proven.The report states we are spending a lot in the first 12 months after stroke (about $175k per person).
Most of the costs in the table below will be spent regardless of outcome. We are investing a lot in the health response to stroke so a mechanism that can deliver a pay off for patients and their families and potentially get younger people back to work post stroke would be compelling for governments.
Economic cost of stroke 2024 report, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.5¢ |
Change
0.045(6.08%) |
Mkt cap ! $100.5M | |||
| Open | High | Low | Value | Volume |
| 76.0¢ | 78.5¢ | 74.0¢ | $41.70K | 55.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5633 | 75.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.5¢ | 1336 | 1 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| AGN (ASX) Chart |